Drug intelligence / Profile preview

AK7

Development stage: Preclinical
Modality: Recombinant Proteins and Enzymes
Administration: Intranasal, Intraperitoneal, Oral

Overview

AK7 is an adenylate kinase protein whose low expression is observed in clear cell renal cell carcinoma (ccRCC). Research indicates that augmenting AK7 expression inhibits ccRCC progression and enhances the effectiveness of anti-PD1 immunotherapy. It regulates the proliferation, invasion, and migration of human ccRCC cell lines and its expression level is associated with the overall survival of ccRCC patients. AK7 is considered a potential prognostic indicator and therapeutic target for ccRCC, with its overexpression in combination with anti-PD1 therapy showing promising potential as a therapeutic approach.

Other names: adenylate kinase 7

Targets

AK (Adenylate kinase isoenzyme 6)

Beyond the preview

Go deeper on AK7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK7.

Explore the full profile